Five genes (TP53, BAI1, ARID2, THSD1, and KIAA2022) mutated in primary cancer and nine genes (ERBB4, ZNF721, NT5E, PDE10A, CA1, NUMB, NBN, ZFYVE16, NCAM1) mutated in peritoneal metastasis may be targets for the effective treatment of peritoneal metastatic gastric adenocarcinoma. This evidence concerns the gene ARID2 and cancer.